Unmet need in the treatment of polymyalgia rheumatica and giant cell arteritis |
| |
| Institution: | 1. Schulich School of Medicine & Dentistry, London, ON, Canada;2. Western University, London, ON, Canada;3. Department of Medicine, Division of Rheumatology, St Joseph''s Health Care, London, ON, Canada;1. Department of Rheumatology, Cambridge University Hospitals NHSFT, Hills Road, Cambridge, CB2 0QQ, UK;2. Seattle Rheumatology Associates, 601 Broadway, Suite 600, Seattle, WA 98122, USA;3. Rheumatology Research Unit, Department of Medicine, University of Cambridge, Cambridge, CB2 0QQ, UK;1. The University of Tennessee Health Science Center, Division of Connective Tissue Disease (Rheumatology), 956 Court Avenue, Coleman Building, Suite G326, Memphis, TN 38163, USA;2. Swedish Medical Center/Providence St. Joseph Health and University of Washington School of Medicine, Seattle Rheumatology Associates, 601 Broadway, Suite 600, Seattle, WA 98102, USA;1. US Department of Veterans Affairs, Tennessee Valley Healthcare System, Dermatology Service and Research Service, Nashville, TN, USA;2. Vanderbilt University Medical Center, Department of Medicine, Division of Rheumatology and Immunology, Nashville, TN, USA;3. University of Notre Dame, South Bend, IN, USA;4. Vanderbilt University Medical Center, Department of Dermatology, Nashville, TN, USA;5. University of Latvia, Institute of Atomic Physics and Spectroscopy, Biophotonics Laboratory, Riga, Latvia;6. Vanderbilt Biophotonics Center, Department of Biomedical Engineering, Vanderbilt University, Nashville, TN, USA;7. Vanderbilt-Ingram Cancer Center, Nashville, TN, USA |
| |
| Abstract: | For decades, aside from prednisone and the occasional use of immune suppressive drugs such as methotrexate, there was little to offer patients with polymyalgia rheumatica (PMR) and giant cell arteritis (GCA). However, there is a great interest in various steroid sparing treatments in both these conditions. This paper aims to provide an overview of our current knowledge of PMR and GCA, examining their similarities and distinctions in terms of clinical presentation, diagnosis, and treatment, with emphasis placed on reviewing recent and ongoing research efforts on emerging treatment. Multiple recent and ongoing clinical trials are demonstrating new therapeutics that will provide benefit and contribute to the evolution of clinical guidelines and standard of care for patients with GCA and/or PMR. |
| |
| Keywords: | Giant cell arteritis Polymyalgia rheumatica Treatment Biologics Glucocorticoids Tocilizumab Emerging therapies |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
